Matthew A Boutros, DO
Internal Medicine · Harbor City
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 4
- Since medical school
- 9 years
- Graduated 2017
Offices
4 locations · Southern California Permanente Medical Group · 11,250 clinicians in this group
Hospitals listed: Kaiser Foundation Hospital - South Bay. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Boutros’s office to ask if they take your plan before you enroll.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Kaiser Foundation Hospital - South BayHarbor City, CAAcute Care Hospital · Voluntary non-profit - Other · No emergency department · Birthing-friendlyPart of Kaiser Permanente, which runs 41 hospitals in 3 statesPatients rate it 3 of 5 · 71% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.33, Oct 2024 – Sep 2025
See every measure and the patient survey for Kaiser Foundation Hospital - South Bay
Behind the star rating — Deaths: 0 better, 1 the same, 0 worse of 1 measures. Safety: 1 better, 5 the same, 0 worse of 6 measures. Readmissions: 0 better, 1 the same, 0 worse of 1 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.33 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.3 (0.23 to 2.37) · 174 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.89 (0.45 to 1.34) | No different | Jul 2022 – Jun 2024 |
| Death rate for stroke patientsComplications and deaths | 13.6 · 258 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 5.3 · 2,741 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.2 (0 to 0.43) · 924 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.26 (0.05 to 0.48) · 965 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.33 (0.75 to 5.9) · 118 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.66 (0 to 3.39) · 25 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.24 (0.54 to 3.93) · 118 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.69 (0 to 18.49) · 33 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.75 (0.22 to 3.28) · 37 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.37 (0 to 1.4) · 715 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.6 · 39 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.746 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 1.076 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.587 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.818 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.9 · 104 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 23 · 689 cases | None | Jul 2023 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 20.3 · 563 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.7 · 37 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19 · 201 cases | None | Jul 2023 – Jun 2025 |
What patients said (510 patients answered, 18% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 74% |
| Nurses "always" communicated well | 76% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 90% |
| Yes, staff "did" give patients information about help after discharge | 90% |
| Doctors "always" explained things so they could understand | 70% |
| Doctors "always" listened carefully | 76% |
| Doctors "always" treated them with courtesy and respect | 85% |
| Patients who gave a rating of "9" or "10" (high) | 71% |
| Staff "always" explained new medications | 74% |
| Nurses "always" explained things so they could understand | 72% |
| Nurses "always" listened carefully | 75% |
| Nurses "always" treated them with courtesy and respect | 83% |
| "Always" quiet at night | 50% |
| "YES", patients would definitely recommend the hospital | 71% |
| Staff "always" explained possible side effects | 49% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
Original Medicare doctor bills
$3,950
Medicare paid this office $3,950 for 22 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 12 | $1,495 | $100 |
Who their Medicare patients are
22 Original Medicare patients in 2024. Average age 59 · 85 and older 0% · Health risk score 1.95. Above the middle of the specialty; the typical internal medicine clinician is at 1.76.
Conditions among them: High blood pressure 64%.
The office billed $10,419, Medicare allowed $4,787 and paid $3,950; for 46 services of 13 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Medicaid work
$20,508 in 2024
Medicaid paid $20,508 for 371 billed services this clinician did in 2024, up to 30 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 170 | $18,661 |
| Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid) | 88 | $1,763 |
| Influenza virus vaccine, trivalent (IIV3), split virus, preservative free, 0.5 mL dosage, for intramuscular use | 15 | $84 |
| TOBACCO NON-USER | 98 | $0 |
| 2024 | 371 | 4 | 30 | $20,508 |
| 2023 | 109 | 3 | 16 | $4,520 |
See the largest Medicaid services in earlier years
2023
| Return visit (30+ min) | 54 | $3,950 |
| Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid) | 30 | $570 |
| TOBACCO NON-USER | 25 | $0 |
Drugs they prescribed that Part D paid
$172,162
Pharmacies billed $172,162 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 5% of their Part D prescriptions (168 of 3,721) in 2024. Above the middle of the specialty; the typical internal medicine clinician is at 1%.
3,365 generic and 305 brand-name prescriptions · $172,162 in drug cost · 115 antibiotic prescriptions to 92 people · 11 antipsychotic prescriptions to people over 65.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Ozempic | 34 | $25,159 | $740 |
| Xarelto | 13 | $15,009 | $1,155 |
| Eliquis | 15 | $14,560 | $971 |
| Jardiance | 17 | $8,911 | $524 |
| Humulin N Kwikpen | 17 | $5,056 | $297 |
See all 76 drugs
| Ozempic | 34 | $25,159 | $740 |
| Xarelto | 13 | $15,009 | $1,155 |
| Eliquis | 15 | $14,560 | $971 |
| Jardiance | 17 | $8,911 | $524 |
| Humulin N Kwikpen | 17 | $5,056 | $297 |
| Atorvastatin | 309 | $3,792 | $12 |
| Alvesco | 26 | $3,445 | $132 |
| Wixela Inhub | 11 | $3,192 | $290 |
| Humulin N | 16 | $3,055 | $191 |
| Amlodipine Besylate | 247 | $2,948 | $12 |
| Pradaxa | 12 | $2,624 | $219 |
| Levothyroxine | 133 | $2,472 | $19 |
| Hydrocodone-Acetaminophen | 99 | $2,369 | $24 |
| Losartan | 178 | $2,307 | $13 |
| Gabapentin | 83 | $2,118 | $26 |
| Lisinopril | 111 | $1,375 | $12 |
| Adacel Tdap | 26 | $1,326 | $51 |
| Potassium Chloride | 38 | $1,304 | $34 |
| Albuterol Sulfate Hfa | 64 | $1,246 | $19 |
| Terazosin | 26 | $1,186 | $46 |
| Rosuvastatin | 99 | $1,161 | $12 |
| Omeprazole | 77 | $874 | $11 |
| Metformin Hcl Er | 95 | $861 | $9 |
| Metoprolol | 84 | $837 | $10 |
| Bisoprolol | 27 | $725 | $27 |
| Hydralazine | 33 | $703 | $21 |
| Metformin | 62 | $696 | $11 |
| Atenolol | 56 | $678 | $12 |
| Trazodone | 45 | $676 | $15 |
| Trospium Chloride | 19 | $665 | $35 |
| Lisinopril-Hydrochlorothiazide | 54 | $664 | $12 |
| Pantoprazole | 53 | $617 | $12 |
| Hydrochlorothiazide | 54 | $608 | $11 |
| Estradiol | 16 | $583 | $36 |
| Meloxicam | 88 | $570 | $6 |
| Acetaminophen-Codeine | 31 | $563 | $18 |
| Azelastine | 32 | $541 | $17 |
| Oxycodone-Acetaminophen | 14 | $519 | $37 |
| Duloxetine | 24 | $502 | $21 |
| Nifedipine Er | 14 | $479 | $34 |
| Nano 2nd Gen Pen Needle | 21 | $471 | $22 |
| Clobetasol Propionate | 21 | $450 | $21 |
| Clopidogrel | 24 | $446 | $19 |
| Simvastatin | 39 | $445 | $11 |
| Veo Insulin | 17 | $439 | $26 |
| Furosemide | 39 | $434 | $11 |
| Prednisone | 46 | $395 | $9 |
| Glipizide | 31 | $389 | $13 |
| Tamsulosin | 23 | $328 | $14 |
| Fluticasone Propionate | 14 | $324 | $23 |
| Mirtazapine | 23 | $317 | $14 |
| Alendronate | 29 | $312 | $11 |
| Allopurinol | 29 | $310 | $11 |
| Amoxicillin-Clavulanate Potass | 22 | $310 | $14 |
| Veo Insulin | 11 | $285 | $26 |
| Mupirocin | 15 | $276 | $18 |
| Cephalexin | 23 | $253 | $11 |
| Pravastatin | 19 | $249 | $13 |
| Spironolactone | 15 | $247 | $16 |
| Neomycin-Polymyxin-Dexameth | 14 | $243 | $17 |
| Ibuprofen | 23 | $209 | $9 |
| Lorazepam | 22 | $202 | $9 |
| Triamcinolone Acetonide | 20 | $202 | $10 |
| Montelukast | 18 | $198 | $11 |
| Losartan-Hydrochlorothiazide | 15 | $177 | $12 |
| Lovastatin | 15 | $175 | $12 |
| Citalopram Hbr | 14 | $169 | $12 |
| Ezetimibe | 15 | $167 | $11 |
| Topiramate | 19 | $162 | $9 |
| Warfarin | 11 | $136 | $12 |
| Isosorbide Mononitrate Er | 12 | $127 | $11 |
| Tramadol | 15 | $116 | $8 |
| Carvedilol | 11 | $104 | $9 |
| Ciprofloxacin | 12 | $102 | $9 |
| Azithromycin | 15 | $97 | $6 |
| Terbinafine | 11 | $91 | $8 |
Year by year
| 2024 | 3,721 | 1,194 | 5% (168) | 8% | $172,162 |
| 2023 | 707 | 311 | 8% (53) | None | $30,179 |
| 2022 | 30 | None | 0% (0) | None | $30,510 |
| 2021 | 167 | 26 | 0% (0) | 37% | $121,808 |
| 2020 | 15 | None | 0% (0) | None | $10,142 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 17 drugs
| Atorvastatin | 35 | $666 | $19 |
| Hydrocodone-Acetaminophen | 38 | $580 | $15 |
| Losartan | 32 | $389 | $12 |
| Amlodipine Besylate | 29 | $378 | $13 |
| Levothyroxine | 13 | $264 | $20 |
| Lisinopril | 20 | $243 | $12 |
| Gabapentin | 13 | $236 | $18 |
| Albuterol Sulfate Hfa | 13 | $229 | $18 |
| Metformin | 15 | $198 | $13 |
| Omeprazole | 17 | $191 | $11 |
| Azelastine | 11 | $186 | $17 |
| Meloxicam | 25 | $154 | $6 |
| Prednisone | 17 | $128 | $8 |
| Metoprolol | 13 | $128 | $10 |
| Metformin Hcl Er | 14 | $125 | $9 |
| Pantoprazole | 11 | $114 | $10 |
| Rosuvastatin | 11 | $107 | $10 |
2021: 1 drug
| Atorvastatin | 11 | $107 | $10 |
Money from drug and device companies
$95 in 2019
A payment is not proof that care is biased.
| Otsuka Pharmaceutical Development & Commercialization | None | $64 | 3 payments
|
| Pfizer | Eliquis | $21 | 1 payment
|
| bioMerieux | Vidas Brahms Pct | $10 | 4 payments
|
See all 8 published payments
| bioMerieux | Meals · 2019-09-19 | Vidas Brahms Pct | $1 |
| bioMerieux | Meals · 2019-09-19 | Vidas Brahms Pct | $1 |
| Pfizer | Meals · 2019-09-12 | Eliquis | $21 |
| Otsuka Pharmaceutical Development & Commercialization | Meals · 2019-08-15 | None | $21 |
| Otsuka Pharmaceutical Development & Commercialization | Meals · 2019-05-09 | None | $21 |
| bioMerieux | Meals · 2019-05-02 | Vidas Brahms Pct | $6 |
| bioMerieux | Meals · 2019-05-01 | Vidas Brahms Pct | $2 |
| Otsuka Pharmaceutical Development & Commercialization | Meals · 2019-02-28 | None | $22 |
Professional record
- NPI
- 1245768787
- Licence
- CA 20A16673
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Internal medicine (207R00000X); Student in a training program (390200000X)
- Mailing address
- 1500 21st St, Sacramento, CA, 95811
- NPI first listed
- 2017-05-29
- NPI last updated
- 2024-05-07
- NPI record certified
- 2020-06-12
This is when the NPI record was last certified, not a medical board exam.
This office lists an electronic records connection.